Evidence map›Paper›PMID 36879346›Full record

ReviewExperimental hematology & oncology2023

Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development.

Xiaoya Ren, Menglong Jiang, Peng Ding, Xiaoyan Zhang, Xin Zhou, Jian Shen, Dong Liu, Xiaolong Yan, Zhiqiang Ma

Open access · goldAbstract readReview
In one paragraph

Review in Experimental hematology & oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Deubiquitinases in cancer.Nature reviews. Cancer · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Xiaoya Ren *Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, 1 Xinsi Road, Xi'an, 710038, China.
Menglong Jiang *Department of Thoracic Surgery, 1st Affiliated Hospital of Anhui Medical University, Hefei City, China.
Peng Ding *Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, 1 Xinsi Road, Xi'an, 710038, China.
Xiaoyan Zhang *Department of Aerospace Medicine, Air Force Medical University, Xi'an, China.
Xin ZhouDepartment of Medical Oncology, Senior Department of Oncology, Chinese PLA General Hospital, The Fifth Medical Center, 28 Fuxing Road, Beijing, 100853, China.
Jian ShenSenior Department of Cardiology, The Sixth Medical Center, Chinese PLA General Hospital and Chinese PLA Medical School, 28 Fuxing Road, Beijing, 100853, China.
Dong LiuState Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, 167 Beilishi Road, Beijing, 100037, China. liudong@fuwaihospital.org.
Xiaolong YanDepartment of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, 1 Xinsi Road, Xi'an, 710038, China. yanxiaolong@fmmu.edu.cn.
Zhiqiang MaDepartment of Medical Oncology, Senior Department of Oncology, Chinese PLA General Hospital, The Fifth Medical Center, 28 Fuxing Road, Beijing, 100853, China. mazhiqiang@301hospital.com.cn.
Air Force Medical University · CNChinese PLA General Hospital · CNAnhui Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNTang Du Hospital · CN

Funding

National Natural Science Foundation of China 81871866, 82173252National Natural Science Foundation of China 82103508Natural Science Foundation of Shaanxi Province 2016SF-308Natural Science Foundation of Shaanxi Province 2019SF-033Natural Science Foundation of Shaanxi Province 2021SF-158Natural Science Foundation of Shaanxi Province 2022SF-145Project of Tangdu Hospital, the Air Force Military Medical University No. 2018 Key TalentsShaanxi Special Support Plan-Program for Leading Talents of Science and Technology Innovation No. 2019 Special Support Plan
6 · The paper itself

Abstract

As significant posttranslational modifications, ubiquitination and deubiquitination, whose balance is modulated by ubiquitin-conjugating enzymes and deubiquitinating enzymes (DUBs), can regulate many biological processes, such as controlling cell cycle progression, signal transduction and transcriptional regulation. Belonging to DUBs, ubiquitin-specific protease 28 (USP28) plays an essential role in turning over ubiquitination and then contributing to the stabilization of quantities of substrates, including several cancer-related proteins. In previous studies, USP28 has been demonstrated to participate in the progression of various cancers. Nevertheless, several reports have recently shown that in addition to promoting cancers, USP28 can also play an oncostatic role in some cancers. In this review, we summarize the correlation between USP28 and tumor behaviors. We initially give a brief introduction of the structure and related biological functions of USP28, and we then introduce some concrete substrates of USP28 and the underlying molecular mechanisms. In addition, the regulation of the actions and expression of USP28 is also discussed. Moreover, we concentrate on the impacts of USP28 on diverse hallmarks of cancer and discuss whether USP28 can accelerate or inhibit tumor progression. Furthermore, clinical relevance, including impacting clinical prognosis, influencing therapy resistance and being the therapy target in some cancers, is depicted systematically. Thus, assistance may be given to future experimental designs by the information provided here, and the potential of targeting USP28 for cancer therapy is emphasized.

Indexed as

BiomarkerCancerPrognosisTherapy resistanceUSP28

Identifiers

PMID36879346
PMCPMC9990303
OpenAlexW4323309543

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.